Exagen Diagnostics, Inc. is a commercial-stage diagnostics company that develops and sells diagnostic tests.
We are committed to providing physicians with clinical tools that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of autoimmune Connective Tissue Disease (CTD).
At Exagen, we continue translating our discovery and development into real solutions that are safe, reliable and cost effective. Our current AVISE® product line encompasses four game-changing products:
Our comprehensive diagnostic tool that is powered by scientifically proven CB-CAPs technology and designed specifically to help distinguish patients that have CTD or similar diseases with overlapping symptoms.
AVISE® SLE Prognostic
Developed as an add-on test to AVISE® CTD, AVISE® Prognostic helps assess a patient’s potential risk for organ involvement through Thrombosis, Cardiovascular events, Lupus Nephritis and Neuropsychiatric Lupus.
AVISE® MTX and AVISE® HCQ are our therapeutic drug monitoring tools designed to help physicians appropriately assess & individualize patient therapy by offering accurate serologic data to inform dosing decisions and determine drug efficacy.
Exagen is committed to providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of ARD/CTD so they, in turn, can help more patients in need. We will continue translating our discovery and development into real solutions that are safe, reliable and cost effective.